Commonwealth Equity Services’s Moleculin Biotech MBRX Stock Holding History

Commonwealth Equity Services’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5	Closed	-$10K	–	2905
2019 Q4	$10K	Hold	5	–	–	﹤0.01%	2871
2019 Q3	$13K	Buy	5 +1	+25%	+$2.58K	﹤0.01%	2814
2019 Q2	$12K	Sell	4 -5	-56%	-$13.6K	﹤0.01%	2757
2019 Q1	$16K	Buy	9 +5	+125%	+$14.9K	﹤0.01%	2714
2018 Q4	$10K	Sell	4 -5	-56%	-$14.4K	﹤0.01%	2649
2018 Q3	$33K	Sell	9 -1	-10%	-$3.77K	﹤0.01%	2719
2018 Q2	$39K	Buy	10 +3	+43%	+$12.3K	﹤0.01%	2678
2018 Q1	$29K	Hold	7	–	–	﹤0.01%	2631
2017 Q4	$29K	Buy	7 +1	+17%	+$4.33K	﹤0.01%	2596
2017 Q3	$30K	Buy	+6	New	+$31.7K	﹤0.01%	2495

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WIC

Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commonwealth Equity Services's MBRX Position: Q1 2020 in Review

Commonwealth Equity Services sold out of Moleculin Biotech (MBRX) in Q1 2020, closing a stake of 5 shares — an estimated $10K sold.

Commonwealth Equity Services first reported a position in MBRX in Q3 2017 and held it in 10 quarters. The position peaked at $39K in Q2 2018. 17 funds tracked by Wall St. Rank hold MBRX as of Q1 2020.

Commonwealth Equity Services reported no remaining Moleculin Biotech position as of Q1 2020 after selling out during the quarter.
Commonwealth Equity Services sold 5 Moleculin Biotech shares in Q1 2020, an estimated $10K.
Commonwealth Equity Services first reported a position in Moleculin Biotech in Q3 2017 and held it in 10 quarters.
Commonwealth Equity Services's Moleculin Biotech position peaked at $39K in Q2 2018.
17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2020.

Based on Commonwealth Equity Services's 13F filing for Q1 2020, filed 11 May 2020.